Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: Behavioral and neurochemical evidence

Psychopharmacology

Volumn 138, Issue 1, 1998, Pages 89-95

  Jentsch, J David ^a   Tran, Anh ^a   Taylor, Jane R ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine; Locomotion; Mesocorticolimbic; Nucleus accumbens; Psychotomimetic; Ventral mesencephalon

Indexed keywords

PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; INTRACEREBRAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE;

EID: 0031826764     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050649     Document Type: Article

References (46)

1. Bowers MB, Hoffman FJ (1984) Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacology 84: 136-137
2. Boyce S, Rupniak NMJ, Steventon MJ, Cook G. Iversen SD (1991) Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primate. Behav Brain Res 42: 115-121
3. Chen J, Paredes W, Lowinson JH, Gardner EL (1990) Δ9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190: 259-262
4. Chen J, Marmur R, Pulles A, Paredes W, Gardner EL (1993) Ventral tegmental microinjection of Δ9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res 621: 65-70
5. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
6. Deutch AY, Tam SY, Freeman AS, Bowers MB, Roth RH (1987) Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 134: 257-264
7. Deutch AY, Clark WA, Roth RH (1990) Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521: 311-315
8. Devine DP, Leone P, Pocock D, Wise RA (1993) Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266: 1236-1246
9. Einhorn LC. Johansen PA, White FJ (1988) Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 8: 100-112
10. Freeman AS, Bunney BS (1984) The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104: 287-293
11. French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8: 649-652
12. Gorelick DA, Balster RL (1994) Phencyclidine (PCP). In: Bloom FE, Kupfer DJ (eds) Psychopharmacology, the fourth generation of progress. Raven Press, New York, pp 1767-1776
13. Grenhoff J, Aston-Jones G, Svensson TH (1986) Nicotinic effects on the firing patterns of midbrain dopamine neurons. Acta Physiol Scand 128:351-358
14. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, Greene RW (1994) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16: 2034-2043
15. Hertel P, Mathe JM, Nomikos GG, Iurlo M, Mathe AA, Svensson TH (1996) Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72: 103-114
16. Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, Uchimura H, Tashiro N (1994) Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 633: 337-342
17. Jaskiw GE, Weinberger DR (1992) Ibotenic acid lesions of the medial prefrontal cortex augment swim-stress-induced locomotion. Pharmacol Biochem Behav 41: 607-609
18. Jaskiw GE, Karoum F, Freed WJ, Phillips I, Kleinman JE, Weinberger DR (1990) Effect of ibotenic acid lesions of the medial prefrontal cortex on amphetamine-induced locomotion and regional brain catecholamine concentrations in the rat. Brain Res 534: 263-272
19. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
20. Jentsch JD, Elsworth JD, Remond DE Jr, Roth RH (1997a) Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J Neurosci 17: 1769-1776
21. Jentsch JD, Andrusiak EA, Tran A, Bowers MB, Roth, RH (1997b) Δ9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic turnover and impairs spatial working memory in the rat: blockade of dopaminergic effects by HA966. Neuropsychopharmacology 16: 426-432
22. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997c) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99
23. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997d) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955
24. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214
25. Lipska BK, Jaskiw GE, Weinberger DR (1994) The effects of combined prefrontal cortical and hippocampal damage on dopamine-related behaviors in rats. Pharmacol Biochem Behav 48: 1053-1057
26. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry 81: 363-369
27. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D. Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307
28. McCullough LD, Salamone JD (1992) Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res 577: 1-9
29. Meltzer HY, Sturgeon RD, Simonovic M, Fessler RG (1980) Phencyclidine as an indirect dopamine agonist. Psychopharmacol Bull 16: 62-65
30. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine - a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927
31. Murase S, Grenhoff J, Chouvet G, Gonon F, Svensson TH (1993) Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157: 53-56
32. Murphy BL, Arnsten AFT, Goldman-Rakic PS, Roth RH (1996) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93: 1325-1329
33. Nestler EJ (1994) Molecular neurobiology of drug addiction. Neuropsychopharmacology 11: 77-87
34. Nisell M, Nomikos GG, Svensson TH (1994) Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44
35. Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, Nishikawa T (1996) Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 22: 304-312
36. Shepard PD, Lehmann H, Connelly ST (1994) Effects of NPC16377, a potent and selective sigma receptor ligand. on the activity of mesencephalic dopamine-containing neurons in the rat. Eur J Pharmacol 265: 141-149
37. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74: 45-55
38. Steinpreis RE, Salamone JD (1993) The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of PCP: a microdialysis and behavioral study. Brain Res 612: 263-270
39. Svensson TH, Mathe JM, Nomikos GG, Schilstrom B, Marcus M, Fagerquist M (1997) Interactions between catecholamines and serotonin: relevance to the pharmacology of schizophrenia. In: Goldstein DS, Eisenhofer G. McCarty R (eds) Catecholamines, bridging basic science with clinical medicine. Academic Press, San Diego, pp 814-818
40. Taber MT, Fibiger HC (1993) Electrical stimulation of the medial prefrontal cortex increases dopamine release in the striatum. Neuropsychopharmacology 9: 271-275
41. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioral effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167: 127-135
42. Verma A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortical function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379
43. White FJ (1996) Synaptic regulation of mesocorticolimbic dopamine neurons. Annu Rev Neurosci 19: 405-436
44. Yoshida M, Yokoo H, Tanaka T, Mizoguchi K, Emoto H, Ishii H, Tanaka M (1993) Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res 624: 277-280
45. Zhang J, Chiodo LA, Freeman AS (1992) Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res 590: 153-163
46. Zhang J, Chiodo LA, Freeman AS (1993) Effects of phencyclidine, MK-801 and 1.3-di(2-tolyl)guanidine on non-dopaminergic midbrain neurons. Eur J Pharmacology 230: 371-374